Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human α-synuclein(1- 120): Implications for lewy body disorders

Journal of Neuroscience

Volumn 26, Issue 15, 2006, Pages 3942-3950

  Tofaris, George K ^a   Reitböck, Pablo Garcia ^a   Humby, Trevor ^b   Lambourne, Sarah L ^b   O'Connell, Mark ^a   Ghetti, Bernardino ^c   Gossage, Helen ^a   Emson, Piers C ^b   Wilkinson, Lawrence S ^b   Goedert, Michel ^d   Spillantini, Maria Grazia ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b BABRAHAM INSTITUTE   (United Kingdom)

^c INDIANA UNIVERSITY   (United States)

^d MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

Author keywords

synuclein; Aggregation; Behavior; Dopamine; Fibril; Nigrostriatal; Parkinson; Tyrosine hydroxylase

Indexed keywords

ALPHA SYNUCLEIN; AMPHETAMINE; MUTANT PROTEIN; TYROSINE 3 MONOOXYGENASE; DOPAMINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; DOPAMINERGIC NERVE CELL; ELECTRON MICROSCOPY; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MOUSE; NEUROPATHOLOGY; NONHUMAN; OLFACTORY BULB; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHY DRAGER SYNDROME; SUBSTANTIA NIGRA; TRANSGENIC MOUSE; ANIMAL; C57BL MOUSE; CBA MOUSE; GENETICS; HUMAN; LEWY BODY; NERVE CELL; PATHOLOGY; PHYSIOLOGY; PROMOTER REGION; RAT;

ALPHA-SYNUCLEIN; ANIMALS; DOPAMINE; HUMANS; LEWY BODIES; LEWY BODY DISEASE; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, TRANSGENIC; NEURONS; OLFACTORY BULB; PARKINSON DISEASE; PROMOTER REGIONS (GENETICS); RATS; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 33646097224     PISSN: 02706474     EISSN: 02706474     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.4965-05.2006     Document Type: Article

References (59)

1. Antony T, Hoyer W, Cherny D, Heim G, Jovin TM, Subramaniam V (2003) Cellular polyamines promote the aggregation of α-synuclein. J Biol Chem 278:3235-3240.
2. Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM, Trojanowski JQ, Iwatsubo T (1998) Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 152:879-884.
3. Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24:197-211.
4. Cai G, Wang HY, Friedman E (2002) Increased dopamine receptor signaling and dopamine receptor-G protein coupling in denervated striatum. J Pharmacol Exp Ther 302:1105-1112.
5. Campbell BCV, Li QL, Culvenor JG, Jäkälä P, Cappai R, Beyreuther K, Masters CL, McLean CA (2000) Accumulation of insoluble α-synuclein in dementia with Lewy bodies. Neurobiol Dis 7:192-200.
6. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, Levecque C, Larvor L, Andrieux J, Hulihan M, Waucquier N, Defebvre L, Amouyel P, Farrer M, Destee A (2004) α-Synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364:1167-1169.
7. Crowther RA, Jakes R, Spillantini MG, Goedert M (1998) Synthetic filaments assembled from C-terminally truncated α-synuclein. FEBS Lett 436:309-312.
8. Crowther RA, Daniel SE, Goedert M (2000) Characterisation of isolated α-synuclein filaments from substantia nigra of Parkinson's disease brain. Neurosci Lett 292:128-130.
9. Duda JE, Giasson BI, Mabon ME, Lee VMY, Trojanowski JQ (2002) Novel antibodies to α-synuclein show abundant striatal pathology in Lewy body diseases. Ann Neurol 52:205-210.
10. Fernandez CO, Hoyer W, Zweckstetter M, Jares-Erijman EA, Subramaniam V, Griesinger C, Jovin TM (2004) NMRof α-synuclein-polyamine complexes elucidates the mechanism and kinetics of induced aggregation. EMBO J 23:2039-2046.
11. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T (2002) α-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4:160-164.
12. Forno LS (1996) Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 55:259-272.
13. 1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. J Neurosci 22:5042-5054.
14. Giasson BI, Duda JE, Murray IVJ, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, Lee VMY (2000) Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions. Science 290:985-989.
15. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VMY (2002) Neuronal α-synucleinopathy with severe movement disorder in mice expressing A53T human α-synuclein. Neuron 34:521-533.
16. Goedert M (2001) Alpha-synuclein and neurodegenerative diseases. Nature Rev Neurosci 2:492-501.
17. Goers J, Uversky VN, Fink AL (2003) Polycation-induced oligomerization and accelerated fibrillation of human α-synuclein in vitro. Protein Sci 12:702-707.
18. Hashimoto M, Takeda A, Hsu LJ, Takenouchi T, Masliah E (1999) Role of cytochrome c as a stimulator of α-synuclein aggregation in Lewy body disease. J Biol Chem 274:28849-28852.
19. Hornykiewicz O (1998) Biochemical aspects of Parkinson's disease. Neurology 51:S2-S9.
20. Ibanez P, Bonnet AM, Débarges B, Lohmann E, Tison F, Pollak P, Agid Y, Dürr A, Brice A (2004) Causal relation between α-synuclein gene duplication and familial Parkinson's disease. Lancet 364:1169-1171.
21. Isles AR, Humby T, Walters E, Wilkinson LS (2004) Common genetic effects on variation in impulsivity and activity in mice. J Neurosci 24:6733-6740.
22. Jakes R, Spillantini MG, Goedert M (1994) Identification of two distinct synucleins from human brain. FEBS Lett 345:27-32.
23. Jakes R, Crowther RA, Lee VMY, Trojanowski JQ, Iwatsubo T, Goedert M (1999) Epitope mapping of LB509, a monoclonal antibody directed against human α-synuclein. Neurosci Lett 269:13-16.
24. Kahle PJ, Neumann M, Ozmen L, Muller V, Jacobsen H, Schindzielorz A, Okochi M, Leimer U, van Der Putten H, Probst A, Kremmer E, Kretzschmar HA, Haass C (2000) Subcellular localization of wild-type and Parkinson's disease-associated mutant α-synuclein in human and transgenic mouse brain. J Neurosci 20:6365-6373.
25. Kahle PJ, Neumann M, Ozmen L, Muller V, Odoy S, Okamoto N, Jacobsen H, Iwatsubo T, Trojanowski JQ, Takahashi H, Wakabayashi K, Bogdanovic N, Riederer P, Kretzschmar HA, Haass C (2001) Selective insolubility of α-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am J Pathol 159:2215-2225.
26. Katzenschlager R, Lees AJ (2004) Olfaction and Parkinson's syndromes: its role in differential diagnosis. Curr Opin Neurol 17:417-423.
27. Krüger R, Kuhn W, Müller T, Woitalla D, Graeber M, Kösel S, Przuntek H, Epplen JT, Schöls L, Riess O (1998) Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat Genet 18:106-108.
28. Lee MK, Stirling W, Xu Y, Xu X, Qui D, Mandir AS, Dawson TM, Copeland NG, Jenkins NA, Price DL (2002) Human α-synuclein-harboring familial Parkinson's disease-linked Ala-53-Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice. Proc Natl Acad Sci USA 99:8968-8973.
29. Li W, West N, Colla E, Pletnikova O, Troncoso JC, Marsh L, Dawson TM, Jäkälä P, Hartmann T, Price DL, Lee MK (2005) Aggregation promoting C-terminal truncation of α-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc Natl Acad Sci USA 102:2162-2167.
30. Liu C-W, Corboy MJ, DeMartino GN, Thomas PJ (2003) Endoproteolytic activity of the proteasome. Science 299:408-411.
31. Liu CW, Giasson BI, Lewis KA, Lee VM, Demartino GN, Thomas PJ (2005) A precipitating role for truncated α-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease. J Biol Chem 280:22670-22678.
32. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, Mucke L (2000) Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders. Science 287:1265-1269.
33. Marazziti D, Golini E, Mandillo S, Magrelli A, Witke W, Matteoni R, Tocchini-Valentini GP (2004) Altered dopamine signaling and MPTP resistance in mice lacking the Parkinson's disease-associated GPR37/parkin-associated endothelin-like receptor. Proc Natl Acad Sci USA 101:10189-10194.
34. Matsuoka Y, Vila M, Lincoln S, McCormack A, Picciano M, LaFrancois J, Yu X, Dickson D, Langston WJ, McGowan E, Farrer M, Hardy J, Duff K, Przedborski S, Di Monte DA (2001) Lack of nigral pathology in transgenic mice expressing human α-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol Dis 8:535-539.
35. Min N, Joh TH, Kim KS, Peng C, Son JH (1994) 5′ upstream DNA sequence of the rat tyrosine hydroxylase gene directs high-level and tissue-specific expression to catecholaminergic neurons in the central nervous system of transgenic mice. Mol Brain Res 27:281-289.
36. Mishizen-Eberz AJ, Guttmann RP, Giasson BI, Day GA, Hodara R, Ischiropoulos H, Lee VMY, Trojanowski JQ, Lynch DR (2003) Distinct cleavage patterns of normal and pathologic forms of α-synuclein by calpain I in vitro. J Neurochem 86:836-847.
37. Murray IV, Giasson BI, Quinn SM, Koppaka V, Axelsen PH, Ischiropoulos H, Trojanowski JQ, Lee VMY (2003) Role of α-synuclein carboxyterminus on fibril formation in vitro. Biochemistry 42:8530-8540.
38. Neumann M, Kahle PJ, Giasson BI, Ozmen L, Borroni E, Spooren W, Müller V, Odoy S, Fujiwara H, Hasegawa M, Iwatsubo T, Trojanowski JQ, Kretzschmar HA, Haass C (2002) Misfolded proteinase K-resistant hyperphosphorylated α-synuclein in aged transgenic mice with locomotor deterioration and in human α-synucleinopathies. J Clin Invest 110:1429-1439.
39. Neumann M, Müller V, Kretzschmar HA, Haass C, Kahle PJ (2004) Regional distribution of proteinase K-resistant α-synuclein correlates with Lewy body disease stage. J Neuropathol Exp Neurol 63:1225-1235.
40. Norris EH, Giasson BI, Hodara R, Xu S, Trojanowski JQ, Ischiropoulos H, Lee VMY (2005) Reversible inhibition of α-synuclein fibrillization by dopaminochrome-mediated conformational alterations. J Biol Chem 280:21212-21219.
41. O'Connell MT, Portas CM, Sarna GS, Curzon G (1991) Effect of p-chlorophenylalanine on release of 5-hydroxytryptamine from the rat frontal cortex in vivo. Br J Pharmacol 102:831-836.
42. Perrin RJ, Payton JE, Barnett DH, Wraight CL, Woods WS, George JM (2003) Epitope mapping and specificity of the anti-α-synuclein monoclonal antibody Syn-1 in mouse brain and cultured cell lines. Neurosci Lett 349:133-135.
43. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanasiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, DiIorio G, Golbe LI, Nussbaum RL (1997) Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276:2045-2047.
44. Rathke-Hartlieb S, Kahle PJ, Neumann M, Ozmen L, Haid S, Okochi M, Haass C, Schulz JB (2001) Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant α-synuclein transgenic mice. J Neurochem 77:1181-1184.
45. Richfield EK, Thiruchelvan MJ, Cory-Slechta DA, Wuertzer C, Gainetdinov RR, Caron MG, Di Monte DA, Federoff HJ (2002) Behavioral and neurochemical effects of wild-type and mutated human α-synuclein in transgenic mice. Exp Neurol 175:35-48.
46. Rochet JC, Conway KA, Lansbury PT (2000) Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse α-synuclein. Biochemistry 39:10619-10626.
47. Sampathu DM, Giasson BI, Pawlyk AC, Trojanowski JQ, Lee VMY (2003) Ubiquitination of α-synuclein is not required for formation of pathological inclusions in α-synucleinopathies. Am J Pathol 163:91-100.
48. Serpell LC, Berriman J, Jakes R, Goedert M, Crowther RA (2000) Fiber diffraction of synthetic α-synuclein filaments shows amyloid-like cross-β conformation. Proc Natl Acad Sci USA 97:4897-4902.
49. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K (2003) α-Synuclein locus triplication causes Parkinson's disease. Science 302:841.
50. Specht CG, Schoepfer R (2001) Deletion of the α-synuclein locus in a subpopulation of C57BL/6J inbred mice. BMC Neurosci 2:11-19.
51. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) α-Synuclein in Lewy bodies. Nature 388:839-840.
52. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M (1998a) α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 95:6469-6473.
53. Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M (1998b) Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett 251:205-208.
54. Takao M, Ghetti B, Yoshida H, Piccardo P, Narain Y, Murrell JR, Vidal R, Glazier BS, Jakes R, Tsutsui M, Spillantini MG, Crowther RA, Goedert M, Koto A (2004) Early-onset dementia with Lewy bodies. Brain Pathol 14:137-147.
55. Thiruchelvam MJ, Powers JM, Cory-Slechta DA, Richfield EK (2004) Risk factors for dopaminergic neuron loss in human α-synuclein transgenic mice. Eur J Neurosci 19:845-854.
56. Tofaris GK, Layfield R, Spillantini MG (2001) α-Synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome. FEBS Lett 509:22-26.
57. Tofaris GK, Razzaq A, Ghetti B, Lilley KS, Spillantini MG (2003) Ubiquitination of α-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J Biol Chem 278:44405-44411.
58. van der Putten H, Wiederhold KH, Probst A, Barbieri S, Mistl C, Danner S, Kauffmann S, Hofele K, Spooren WP, Ruegg MA, Lin S, Caroni P, Sommer B, Tolnay M, Bilbe G (2000) Neuropathology in mice expressing human α-synuclein. J Neurosci 20:6021-6029.
59. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, Llorens V, Gomez Tortosa E, del Ser T, Munoz DG, de Yebenes JG (2004) The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55:164-173.